Author Question: A patient who is undergoing treatment for cytomegalovirus received his first dose of IV ganciclovir ... (Read 68 times)

awywial · **on:** Jul 23, 2018

A patient who is undergoing treatment for cytomegalovirus received his first dose of IV ganciclovir 3 days ago. When reviewing this patient's most recent blood work, what abnormality should the nurse most likely attribute to the use of this drug?

A) Hemoglobin 17 g/dL (high normal)
B) INR 3.8 (high)
C) Platelet count 118,000/mm3 (low)
D) Leukocytes 11,900/mm3 (high)

Question 2

A child is prescribed therapy with glucocorticoids. The child is placed on alternate-day therapy. What is the advantage of alternate-day therapy in this child?

A) The child will have less chance of infection.
B) It will protect the child from hyperglycemia.
C) The child will have less chance of hypertension.
D) Adherence will be increased.

Liddy · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

C
Feedback:
Ganciclovir causes granulocytopenia and thrombocytopenia in 20 to 40 of recipients, often during the first 2 weeks of therapy. Leukocytosis, increased hemoglobin, and hypocoagulation are not typical adverse effects associated with ganciclovir.

Answer to Question 2

A
Feedback:
Intermediate-acting glucocorticoids are the drugs of choice for alternate-day therapy and will decrease the susceptibility of infection. Alternative-day therapy will not protect from hyperglycemia. Alternate-day therapy will not affect blood pressure. Alternate-day therapy is not used as a strategy for improving adherence.